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ABSTRACT
Ecto-nucleotidases hydrolyze extracellular nucleotides. Nucleotides are amongst
the most ubiquitous messenger substances in the vertebrate body. Receptors for
nucleotides are expressed on the surface of essentially every cell and many cells
carry several types of nucleotide receptors. Several families of ecto-nucleotidases
have been identified that differ in tissue distribution and functional properties.
They modulate ligand availability at nucleotide and adenosine receptors. Ecto-
nucleotidases were first identified in the 1940ies. Work of the past two decades has
unraveled molecular identities and important functional properties. Using targeted
gene deletion clear examples highlighting the importance of ecto-nucleotidases in
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nucleotide and adenosine signaling have been elaborated. These reach from the
control of blood flow and angiogenesis to the modulation of immune functions and
neural development. Specific ecto-nucleotidases are associated with stem cells in
the adult mammalian brain, implicating a role of nucleotides and nucleosides
in the control of adult neurogenesis. Ecto-nucleotidases represent important
therapeutic targets to interfere with P2 or P1 receptor-mediated receptor signaling
pathways. The development of high throughput assays promises a considerable
acceleration in the development of subtype-specific ecto-nucleotidase inhibitors.
Key words: Alkaline phosphatase.—ATP.—Ecto-ATPase.—Neurogenesis.—5’-
nucleotidase.
RESUMEN
Ecto-nucleotidasas, propiedades moleculares e impacto funcional
Las ecto-nucleotidasas hidrolizan los nucleótidos extracelulares. Los nucleóti-
dos se encuentran entre las sustancias mensajeras más ubicuas en vertebrados. Los
receptores de nucleótidos se expresan en la superficie de prácticamente todas las
células y muchas células expresan varios tipos de estos receptores. Se han identi-
ficado varias familias de ecto-nucleotidasas, las cuales difieren en su distribución
tisular y en sus propiedades funcionales. Modulan la disponibilidad del ligando en
los receptores de nucleótidos y de adenosina. Las ecto-nucleotidasas fueron iden-
tificadas por primera vez en la década de 1940. Los trabajos de las dos últimas
décadas han mostrado sus características moleculares así como importantes pro-
piedades funcionales. Utilizando delecciones génicas dirigidas se han mostrado
claros ejemplos destacables de la importancia de las ecto-nucleotidasas en la seña-
lización por nucléotidos y adenosina. Estos ejemplos abarcan desde el control del
flujo sanguíneo y la angiogénesis a la modulación de las funciones inmunes y el
desarrollo nervioso. Ecto-nucleotidasas específicas están asociadas con células
madre en el cerebro adulto de mamífero, implicando un papel de los nucleótidos
y nucleósidos en el control de la neurogénesis adulta. Las ecto-nucleotidasas repre-
sentan importantes dianas terapéuticas para interferir en las vías de señalización
mediadas por receptores P2 o P1. El desarrollo de ensayos de alto rendimiento
promete una considerable aceleración en el desarrollo de inhibidores de subtipos
específicos de ecto-nucleotidasas.
Palabras clave: Fosfatasa alcalina.—ATP.—Ecto-ATPasa.—Neurogénesis.—5´-
nucleotidasa.
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INTRODUCTION
Nucleotides are amongst the most ubiquitous messenger
substances in the vertebrate body. Receptors for nucleotides are
expressed on the surface of essentially every cell and many cells
carry several types of nucleotide receptors (1). The concept of
purinergic signaling as we understand it today reaches back into the
1960ies with a number of basic discoveries made by Geoffrey
Burnstock in Melbourne (2). ATP was the first nucleotide whose
signaling function was discovered, but it was later shown that also
other nucleotides evoke cellular responses. These include ADP, UTP,
UDP, nucleotide sugars and NAD+ as well as a variety of dinucleoside
polyphosphates (3, 4). The concept of nucleotide receptors was
initially developed on pharmacological and physiological grounds
and subsequently corroborated by the molecular cloning and
heterologous expression of nucleotide receptors. Nucleotide receptors
(P2 receptors) function either as cation channels (P2X receptors) or
are G-protein-coupled (P2Y receptors) (1). ATP can be released from
cells via constitutive or regulated pathways (5). Extracellular
nucleotides are inactivated by hydrolysis via ecto-nucleotidases with
the respective nucleoside as the final hydrolysis product that can be
salvaged via specific transporters (6). In the case of adenosine,
additional cellular functions can be mediated by P1 receptors.
Diadenosine polyphosphates act on a variety of receptors, including
P1, P2X and P2Y receptors (7) and endogenous dinucleotide
receptors (8).
THE BEGINNING
ATP was first identified in muscle extracts in 1929 independently
by Karl Lohmann at the Kaiser Wilhelm Institute for Biology in
Berlin and by Cyrus Hartwell Fiske and Yellagaprada SubbaRow at
Harvard University (9) (Figure 1). At that time, this discovery evoked
rather little response and the role of ATP as a high energy compound
and its role in carbohydrate breakdown were only realized during
the years following. The same year witnessed the first publication of
a biological activity of AMP and adenosine (on the heart and
vasculature) (10). In 1934 J. H. Gillespie in Belfast demonstrated a
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biological action of ATP on several mammalian tissues (11). Other
support for a potential extracellular function of ATP came from the
discovery of its storage inside secretory granules of a variety of cells
such as dense granules of blood platelets (12, 13), chromaffin
granules (14, 15) and later adrenergic (16) and cholinergic (17)
synaptic vesicles (18). ATP was found to be costored with the
neurotransmitters noradrenaline and acetylcholine. On nerve
stimulation, ATP is depleted from cholinergic synaptic vesicles
in parallel with acetylcholine and replenished together with
acetylcholine during a subsequent period of rest. Adenosine taken up
into cholinergic nerve terminals via a high affinity transporter is
immediately phosphorylated and ends up again in synaptic vesicles
in the form of ATP that is coreleased with acetylcholine (adenosine
cycle) (19, 20).
The notion of cell surface-located ATPases reaches back into the
1940ies. To the best of knowledge, first cell surface-located hydrolysis
of ATP was observed in carefully washed bull spermatozoa by T. Mann
in Cambridge in 1945 (21). More detailed reports followed on the
hydrolysis of ATP and ADP by intact yeast cells (22) and subsequently
in human erythorcytes (23), ascites tumor cells (24) and nucleated
avian erythrocytes (25, 26). First evidence for an association of ATPase
activity with peripheral nerves was obtained by Abood and Gerard in
1954 (27). The pioneering methodological work of Wachstein and
Meisel (1957) (28) paved the way for the enzyme cytochemical
demonstration of ATP hydrolysis at the electron microscopic level that
revealed the ubiquity of cell surface located ATPase activity. Essner et
al. (1958) (29) were among the first to use the electron microscope to
localize adenosine triphosphatase and 5’-nucleotidase activities at
the plasma membrane. The term ecto-ATPase was coined in 1957
by W.A. Engelhardt from the Academy of Sciences in Moscow on
the basis of his findings of surface-located ATPase activity on avian
blood cells (25). He also introduced the terms ectoenzyme and
ectoapyrase (26). Yet, the functional role of extracellular ATP
hydrolysis remained a matter of speculation. As for the concept of
nucleotide receptors, the concept of extracellular nucleotide
hydrolysis was met by the scientific community with great skepticism.
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FIGURE 1. Hallmarks of nucleotide research with particular emphasis on
signaling via extracellular nucleotides. ATP was first discovered in 1929 and
in the 1980ies and 1990ies the molecular and functional identity of prototype
members of all ecto-nucleotidase families and of nucleoside and nucleotide
receptor families was uncovered (for references see text). Ado, adenosine;
A2 receptor, adenosine A2 receptor; AP, alkaline phosphatase (human placental).
HERBERT ZIMMERMANN Y COLS. AN. R. ACAD. NAC. FARM.
542
This skepticism was eventually overcome by the molecular
cloning, heterologous expression, analysis of membrane topology
and functional characterization of the molecular players involved.
The first ones were the nucleotide-hydrolyzing enzymes placental
alkaline phosphatase (30), ecto-nucleotide pyrophosphatase/
phosphodiesterase-1 (31) and ecto-5’-nucleotidase (32), followed by
the first adenosine (A2) receptor (33), the first P2Y receptors (34, 35)
and P2X receptors (36, 37) and finally the molecular identification
of the first mammalian member of the ecto-nucleoside triphosphate
diphosphohydrolase family NTPDase1 (CD39) (38, 39).
MULTIPLICITY OF ECTO-NUCLEOTIDASES
We now know that extracellular nucleoside triphosphates and -
diphosphates can be hydrolyzed by a variety of ecto-nucleotidases
belonging to three different enzyme families with several members
each (Figure 2, Table 1). These include the E-NTPDases (ecto-
nucleoside triphosphate diphosphohydrolases) (40, 41), the E-NPPs
(ecto-nucleotide pyrophosphatase/phosphodiesterases) (42-44)
and the alkaline phosphatases (45, 46). As for the adenosine and
nucleotide receptors (47), the identification and molecular cloning
of an increasing number of these enzymes required an adjustment
of nomenclature. Scientists at the Second International Workshop
on Ecto-ATPases proposed that all E-NTPDase family members
be termed as NTPDase proteins and all members of the E-NPP-
family as NPPs, classified in order of discovery and characterization
(40, 48). These enzymes vary considerably regarding substrate
preference and affinity, product formation, cation dependence
and pH optimum. Recently, an ecto-form of the mitochondrial
F1Fo ATP synthase/F1 ATPase has been implicated in extracellular
ATP synthesis or also hydrolysis. The subunit arrangement of
the ecto-form and its functional properties require further
characterization (49).
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FIGURE 2. Membrane topology of ecto-nucleotidases and other nucleotide-
metabolizing enzymes. In contrast to NPP1 and NPP3 that are type 2 membrane
proteins, NPP2 is a secreted protein. Soluble adenosine deaminase (ADA) is bound
to the cell surface via the GPI-anchored protein CD26 (dipeptidyl peptidase IV).
CD38 and CD157 are NAD glycohydrolases (NADases). ARTs are ADP-
ribosyltransferases that (in part) also metabolize NAD+. Substrates and products
are given in Table 1. Not shown: Nucleoside diphosphate kinase and F1Fo
ATPsynthase/F1 ATPase. Extracellular ATP can also serve as a co-substrate for
ecto-protein kinases.
Extracellular NAD+ can be cleaved by E-NPPs but also by two
closely related families of extracellular NAD+ metabolizing enzymes,
NAD glycohydrolases (NADases) (CD38, CD157) and mono(ADP-
ribosyl)transferases (ARTs) (50) (Table 1). Ecto-5‘-nucleotidase, of
which only a single gene exists in the mammalian genome, hydroly-
ses only nucleoside monophosphates (51, 52). Additional surface-
located enzymes catalyze nucleotide interconversion and thus the
extracellular synthesis of nucleoside triphosphates and diphospha-
tes. These include ecto-nucleoside diphosphokinase and the adenine
nucleotide-specific ecto-ATP:AMP phosphotransferase (adenylate ki-
nase, myokinase) (53, 54) (Figure 2). Obviously, ecto-nucleotidases
are even more diverse than nucleotide receptors and we are only
beginning to understand their specific function in the context of the
modulation of ligand availability at nucleotide and nucleoside recep-
tors. Some of the principal properties of ecto-nucleotidases are brie-
fly summarized below.
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TABLE 1. Ecto-nucleotidases and other enzymes metabolizing extracellular
nucleotides
Inhibitors
ARL 67156, 8-BuS-
ATP,
polyoxometalates,
P2 receptor
antagonists
P2 receptor
antagonists,
heparin, heparan
sulphates
Levamisole, L-
homoraginine
L-phenylalanine
AOPCP
Ap5A
NAD+ analogues
Oligomycin
Family
Ecto-nucleoside
triphosphate
diphos-
phohydrolases
Ecto-nucleotide
pyrophosphatase/
phospho-
diesterases
Alkaline
phosphatases
Ecto-5’-
nucleotidase
Adenylate kinase
NAD+
glycohydrolases
(NADases)
Mono(ADP-
ribosyl)
transferases
Nucleoside
diphosphate
kinase
ATP-synthases
Surface-located
forms
NTPDase1,
NTPDase2,
NTPdase3,
NTPDase8
NPP1, NPP3,
NPP2, secreted
Kidney/bone/liver
[= tissue non-
specific form,
TNAP],
Placental,
Intestinal, Germ-
cell
Ecto-5’-
nucleotidase
AK1-6, not
identified
CD38, CD157
ART1-ART5
ART2
nm23-M1-6, not
identified
Ecto-F1Fo
ATPsynthase/
F1 ATPase
Substrates
NTP, NDP
NTP (NDP)
dinucleoside
polyphosphates
NAD+
UDP-glucose
NTP, NDP,
NMP
NMP
ADP or AMP +
ATP
NAD+
NAD+
NAD+
N1TP, N2DP
ADP
Final product
NMP
NMP + PPi, (Pi)
NMP + Npn-1
AMP +
nicotinamide
mononucleotide
UMP + Gluose-6-
phosphate
Nucleoside
Nucleoside
AMP + ATP or
ADP
ADP-ribose and
nicotinamide,
(cyclic ADP-
ribose)
ADP-ribosylated
protein
ADP-ribose and
nicotinamide
N1DP, N2TP
ATP
Ap5A, P
1P5-di (adenosine-5') pentaphosphate; ARL 67156, 6-N,N-diethyl-D-β,γ -dibromomethylene ATP;
BuS-ATP, 8-thiobutyladenosine 5’-triphosphate; AOPCP, α,β-methylene adenosine 5’-diphosphate; both
ATP synthesis and ATP-hydrolysis has been reported for ecto-F1Fo ATPase. The subtype of surface-located
adenylate kinase and nucleoside diphosphate kinase has not been identified.
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E-NTPDases
This enzyme family comprises eight different members of which
only NTPDase1-3 and 8 are typical cell surface-located enzymes, with
two transmembrane helices and a large extracellular domain carrying
the catalytic site (40, 41, 55) (Figure 2). Of the intracellular enzymes
(NTPDase4-7) that hydrolyze nucleoside diphosphates and/or
triphosphates but not ATP, NTPDase6 and NTPDas6 can be released
in soluble form. All enzymes are members of the actin/HSP70/sugar
kinase superfamily with whom they share common sequence motifs
as well as a conserved secondary structure (56, 57). Structural
predictions have been derived from mutagenic analyses and
computational modeling based on homology with a bacterial
exopolyphosphatase (58). The ectoenzymes form homooligomeric
complexes. All members of the NTPase gene family are also expressed
in Xenopus (59).
The surface-located NTPDases1-3 and 8 reveal a partially
overlapping tissue distribution but apparently are expressed by
different cells (55, 60). NTPDase1 corresponds to the lymphoid cell
activation antigen CD39. It is expressed by cells of the immune
system, the quiescent vascular endothelium and a variety of other
cells including the microglia of the brain (41, 61, 62). NTPDase2 is
associated amongst others with the adventitial surfaces of the
muscularized vessels, microvascular pericytes, portal fibroblasts from
the liver, within taste papillae, the inner ear, with immature and
nonmyelinating Schwann cells of the peripheral nervous system (63)
and neural progenitor cells of the adult rodent brain (41, 64, 65).
NTPDase3 is expressed in brain and in a variety of other tissues (56,
66, 67) whereas expression of NTPDase8 in the brain is very low or
absent (55).
Importantly, the hydrolysis rates for nucleoside diphosphates vary
considerably between the four enzymes (60, 68). NTPDase2 stands
out for its high preference for nucleotide triphosphates and thus is
also referred to as an ecto-ATPase. In addition the enzymes differ
regarding product formation. Whereas NTPDase1 hydrolyzes ATP
directly to AMP with the production of minor amounts of free ADP,
ADP accumulates extracellularly on ATP hydrolysis by NTPDase2.
NTPDase3 and NTPDase8 reveal intermediate patterns of product
HERBERT ZIMMERMANN Y COLS. AN. R. ACAD. NAC. FARM.
546
formation. These differences in catalytic properties differentially
affect the scavenging or the production of agonists for P2 receptors
by individual enzymes or combinations of these.
E-NPPs
The three nucleotide-hydrolyzing members of the E-NPP family,
NPP1 to NPP3, hydrolyze 5’-monodiester bonds in nucleotides
and their derivatives, resulting in the release of 5’-nucleoside
monophosphates. E-NPPs are members of the alkaline phosphatase
superfamily and their catalytic core structure reveals close similarity
to the superfamily of phospho-/sulfo-coordinating metalloenzymes
comprising alkaline phosphatases, phosphoglycerate mutases, and
arylsulfatases (69, 70). All three enzymes share a typical modular
structure. NPP1 and NPP3 are type II transmembrane glycoproteins
that also occur in soluble form whereas NPP2 is secreted. The
enzymes have a broad tissue distribution (42, 43). NPP1 was
originally discovered at the surface of lymphocytes as plasma cell
differentiation antigen (PC-1). Physiological substrates of these
enzymes include ATP, NAD+, nucleotide sugars and dinucleoside
polyphosphates (42, 43, 71). ATP is an inhibitor of diadenosine
polyphosphate hydrolysis (72). In several tissues investigated,
diadenosine polyphosphates are hydrolyzed considerably more slowly
than ATP, implicating a prolonged extracellular half-life of these
nucleotides (73). Nucleotide hydrolysis by NPPs has a very alkaline
pH optimum (8.5 - 9.0), comparable to that of alkaline phosphatases.
In addition to its nucleotidase activity, the splice variant of NPP2,
autotaxin, also exerts lysophospholipase D activity (74). The four
additional and non-nucleotide-hydrolyzing members of the E-NPP
family NPP4 to NPP7 are shortened at the N terminus, with
presumptive inverse membrane topography. Of these, NPP6 and
NPP7 exhibit lysophospholipase-C or choline glycerophosphodiester
phosphodiesterase activity (43).
NPP1 to NPP3 hydrolyze ligands of nucleotide receptors. In the
case of nucleoside triphosphates, hydrolysis typically proceeds
directly to the nucleoside monophosphate with the formation of PPi
(Table 1). This circumvents activation of receptors for nucleoside
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diphosphates. NPP1 is a major source of extracellular PPi which is
highly relevant in the control of bone mineralization (44). Hydrolysis
of dinucleoside polyphosphates (ApnAs) by NPPs is asymmetric and
involves the α, β-pyrophosphate bond, resulting in the production
of AMP and Apn-1 (71). Thus, hydrolysis of Ap5A, Ap4A, or Ap3A yields
adenosine tetraphosphate, ATP and ADP, respectively (72). This could
in turn lead to the additional or also continued activation of P2
receptors, depending on available receptor subtype. NAD+ is
hydrolyzed by NPPs to AMP and nicotinamide mononucleotide.
Alkaline phosphatases
The four human isoforms of alkaline phosphatases (kidney/bone/
liver [= tissue non-specific form, TNAP], placental, intestinal and
germ-cell are dimers, share a glycosylphosphatidyl inositol (GPI)
anchor and can give rise to soluble forms. The distribution of
isoforms varies to some extent between humans and rodents (45,
46). Alkaline phosphatases are non-specific phosphomonoesterases
that degrade nucleoside 5’-tri-, -di-, and -monophosphates, hydrolyze
inorganic pyrophosphate (PPi) and also release inorganic phosphate
from a large variety of organic compounds, including proteins. Thus,
alkaline phosphatases are capable of directly producing the P1
receptor agonist adenosine from extracellular ATP. Their pH
optimum is in the high alkaline range but they hydrolyze ATP also
at a pH of 7.4. Alkaline phosphatases certainly play an important
role in purine salvage but they can also modulate purinergic
signaling. The crystal structures of bacterial, shrimp and human
enzymes have been resolved (45, 75).
NUCLEOTIDE SYNTHESIS AND INTERCONVERSION
Ecto-nucleoside diphosphate kinase interconverts nucleoside
5’-di- and -triphosphates, leading to the formation of e.g. UTP and
ADP from ATP and UDP or of ATP and UDP from UTP and ADP.
This can result in the mutual activation or inactivation of receptors
for ATP, ADP, UTP and UDP. Together with other ecto-nucleotidases,
ecto-nucleoside diphosphate kinase may maintain low steady state
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concentrations of nucleoside triphosphates at the cell surface, leading
to tonic receptor activation. Ecto-ATP:AMP phosphotransferase
(adenylate kinase, myokinase) catalyzes the extracellular formation
of ATP and AMP from ADP and vice versa (53, 54, 76).
ECTO-5’-NUCLEOTIDASE
The GPI-anchored ecto-5’-nucleotidase (CD73) is a Zn2+-binding
dimeric protein that hydrolyzes nucleoside monophosphates to their
respective nucleosides. It differs from intracellular 5’-nucleotidases
(52). The crystal structure of the periplasmic 5’-nucleotidase from
Escherichia coli (77) serves as a model for the structural analysis
of the related mammalian enzyme (78). Like alkaline phosphatase,
ecto-5’-nuceotidase can catalyze the formation of adenosine from
extracellular AMP and the concomitant activation of P1 adenosine
receptors. ATP and ADP inhibit AMP hydrolysis, resulting in feed
forward inhibition of ecto-5’-nucleotidase (79). The enzyme is broadly
distributed within various tissues and associated also with the
vascular endothelium but apparently with an expression pattern
different from alkaline phosphatase (TNAP) (80).
CD38 AND RELATED PROTEINS
NAD glycohydrolases (NADases) (CD38, CD157) and ADP-
ribosyltransferases (ARTs) represent two closely related families of
extracellular NAD+ metabolizing enzymes that cleave NAD+ at the
adenosine diphosphoribosyl-nicotinamide linkage. NADases convert
NAD+ to ADP-ribose and nicotinamide and due to their additional
ADP-ribosyl cyclase activity also to cyclic ADP-ribose. ARTs also
transfer ADP ribose to acceptor proteins, including the P2X7 receptor
(81, 82). The extracellularly formed cyclic ADP-ribose is considered
to be transported into the cell where it activates Ca2+ release from
intracellular stores (50).
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ECTO-NUCLEOTIDASES AND PURINERGIC SIGNALING
It is obvious that the broad spectrum of ecto-nucleotidase enzyme
species as well as the considerable variability of their catalytic
properties allows for multiple modulations of purinergic signaling-
depending on type and combination of enzymes as well as receptors.
Ecto-nucleotidases could for example (1) inactivate P2 receptors
sensitive to nucleoside triphosphates by directly hydrolyzing a
nucleoside triphosphate to the inactive nucleoside monophosphate,
(2) inactivate P2 receptors sensitive to nucleoside triphosphates and
at the same time (by generating the nucleoside diphosphate)
transiently or tonically produce agonists for nucleoside diphosphate
receptors, (3) inactivate receptors for e.g. diadenosine polyphosphates
and at the same time generate the physiologically active ligands Ap4,
ATP or ADP, (4) prevent P2 receptor desensitization, (5) generate the
P1 receptor agonist adenosine from extracellular ATP. Following
release of ATP, this allows for complex signaling mechanisms in
cellular networks that can involve both, P2 and P1 receptor activation.
Therefore a detailed analysis of nucleotide signaling pathways
requires information on the identity and exact location of both ecto-
nucleotidase and purinergic receptor subtypes for each individual
cellular setting investigated.
In vitro studies using recombinant proteins, mimicking different
combinations of receptors and enzymes underline this notion. (83).
The data demonstrate that ecto-nucleotidases can selectively modulate
the effective agonist concentration at P2Y1 receptors on identical
or neighboring cells, either by degrading ATP or by generating
ADP from ATP. In addition, colocalized ecto-nucleotidases, by
reducing levels of constitutively released nucleotide, reduce receptor
desensitization. Preventing receptor desensitization following tonic or
acute nucleotide release may be an important function of ecto-
nucleotidases.
This close interaction between enzymes and ecto-nucleotidases
is also of immediate relevance in situ. The interaction between
the two ecto-nucleotidases NTPDases1 and NTPDase2 is of pivotal
importance for the control of vascular platelet activation. NTPDase1
is expressed by endothelial cells, vascular smooth muscle cells and
to a small extent by red blood cells and platelets. Due to its capacity
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to hydrolyze ATP to AMP and ADP to AMP it blocks platelet
aggregation in response to ADP thus supporting blood flow.
Accordingly, NTPDase1 knockout mice reveal increased infarct
volumes. Infusion of soluble derivatives of NTPDase1 or soluble plant
apyrases improves blood flow and tissue reperfusion following
ischemia and in tissue transplants (41, 84). NTPDase2 produces ADP
from ATP and thus promotes platelet activation. The enzyme is
located at adventitial surfaces of the muscularized vessels,
microvascular pericytes of some tissues and organs as the heart
and the stromal cells and would potentially favor ADP-induced
platelet aggregation at sites of vessel injury and thus support
hemostasis (85, 86).
In another setting, portal fibroblasts were suggested to regulate
bile duct epithelial proliferation via expression of NTPDase2.
NTPDase2 inhibits and knockdown of NTPDase2 by RNA
interference increases the proliferation of epithelial cells, apparently
by compromising their nucleotide scavenging effect. Loss of portal
fibroblast NTPDase2 following bile duct ligation may thus mediate
the bile ductular proliferation typical of obstructive choleostasis (87).
BROAD FUNCTIONAL IMPACT OF ECTO-NUCLEOTIDASES
As shown by a considerable number of immunocytochemical or
enzyme histochemical studies defined ecto-nucleotidases are
expressed in specific tissues or cellular systems. In many cases a
resolution at the electron microscopic level would be desirable to
identify their exact localization and site of action. This particularly
applies to the nervous system. Yet, the demonstration of the
expression of an enzyme in a defined cellular setting does not permit
an immediate anticipation of its functional impact. This depends on
the actual catalytic activity and the scenario of the surrounding
purinergic receptors. But the identification of ecto-nucleotidases may
serve as a first indicator of a functional involvement of nucleotide
signaling pathways. Presently, the best tool for studying the
functional impact of a particular ecto-nucleotidase in a defined
purinergic signaling pathway is the use of specific high affinity
inhibitors (if available), the knockdown by RNA interference or the
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targeted deletion of the respective gene. The addition of the soluble
ATP- and ADP hydrolyzing enzyme apyrase can corroborate the
involvement of nucleotide signaling but does not provide immediate
evidence for a participation of endogenous ecto-nucleotidases.
TARGETED DELETION OF ECTO-NUCLEOTIDASES
The targeted deletion of NTPDase1 has yielded important insight
into the functional role of NTPDase1 in vascular control (88) and in
the immune system (89). Inactivation of mouse intestinal alkaline
phosphatase (IAP) revealed a functional involvement in fat
absorption (90). Knockout mice for NPP1 have been characterized in
addition to a natural mutant of NPP1 (tiptoe walking mouse).
Deficiency of NPP1 is associated with pathological calcification of
ligaments and joint capsules (42). Mutations in the TNAP gene in
humans cause hypophosphatasia involving defective mineralization
of hard tissue. Mice lacking TNAP can serve as a model for the
infantile form of hypophosphatasia and also reveal deficiencies in
nervous system development and a number of severe tissue
abnormalities (91, 92). Knockouts of the embryonic form of alkaline
phosphatase or double knockouts for TNAP and the embryonic form
do not reveal additional phenotypes (91). Double knockouts for TNAP
and NPP1 underline the opposing and reciprocal actions of NPP1
and TNAP in the production and hydrolysis of extracellular PPi and
thus in the control of bone mineralization, respectively. They suggest
that both TNAP and NPP1 are potential therapeutic targets for the
treatment of mineralization disorders (44, 93, 94). These effects on
mineralization appear to reflect the balance of extracellular PPi and
Pi levels controlled by the two enzymes rather than P2 or P1 receptor-
mediated mechanisms.
NPP2 (autotaxin) knockouts die at embryonic age and
investigations on heterozygous mice underline the notion that
phospholipase D activity and thus the production of lysophosphatidic
acid represents a major functional role of the enzyme (95). Mice in
which the ecto-5’-nucleotidase gene is disrupted do not reveal an
apparent phenotype when kept under normal conditions but detailed
studies corroborated the physiological importance of the enzyme in
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the formation of extracellular adenosine from extracellular nucleotide
in several tissue functions (96). Deletion of CD38 underlined the role
of the protein in regulating the humoral immune response (97) but
also revealed its participation in osteoclast formation and bone
resorption (98). Similarly, deletion of CD157 implicates a role in B cell
development and antibody production (99).
From these and from many additional studies it has become
evident that ecto-nucleotidases are involved in the control of a large
variety of physiological and pathophysiological functions mediated
by nucleotides (41-44, 50, 96, 100, 101). Examples include epithelial
ion and fluid transport (5’-nucleotidase), tissue barrier functions such
as the transmigration of leucocytes through the vascular endothelium
(5’-nucleotidase; CD38), blood flow, including platelet aggregation
and ischemia and reperfusion (5’-nucleotidase, NTPDase1),
angiogenesis and vascular remodeling (NTPDase1), renal function
(5’-nucleotidase), hypoxia (5’-nucleotidase, NTPDase1), the immune
system (CD38, NPP1, NTPDase1, 5’-nucleotidase), the function of
airway epithelia including chronic lung disease (NPPs, NTPDases,
alkaline phosphatase, ecto-adenylate kinase, ecto-5’-nucleotidase) or
bone and cartilage mineralization (NPP1, TNAP). In the nervous
system, ecto-nucleotidases have been implicated in a considerable
variety of functions, including synaptic signal transmission,
microglial function and neurogenesis. There is increasing evidence
for an involvement of ecto-nucleotidases in sensory transmission as
for example for NTPDase1 to NTPDase3 in the inner ear (102).
INHIBITORS OF ECTO-NUCLEOTIDASES
Inhibition of ecto-nucleotidases represents an important mode to
target nucleotide signaling pathways. Obviously, targeting ecto-
nucleotidases will affect not only nucleotide signaling per se but also
additional cooperative or opposing signaling pathways. Ideally, ecto-
nucleotidase inhibitors should neither be P2 or P1 receptor agonists
or antagonists nor substrates of ecto-nucleotidases (60, 103).
Inhibitors of NTPDases (Table 1) include non-hydrolyzable
nucleotide analogues and P2 receptor antagonists. Among the
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compounds that have been reported to inhibit hydrolysis of ATP
without significantly acting on purinoceptors are the structural
analogues of ATP, ARL 67156 (FPL 67156) (6-N,N-diethyl-D-β,γ-
dibromomethylene ATP) (104-106) and 8-thiobutyladenosine 5’-
triphosphate (8-BuS-ATP) (107) and 1-naphthol-3, 6-disulfonic acid
(BG0136) (103). Recently, high throughput assay systems for ecto-
nucleotidase analysis have been developed and polyoxometalates
have been implicated as a new class of very potent NTPDase
inhibitors (108, 109). These substances can be applied systemically
and hold promise to finally provide a pharmacological access to this
enzyme family. Importantly, the potency of these and other inhibitors
can vary considerably between individual members of the E-NTPDase
family (109-111). This opens the possibility of isoform-specific ecto-
nucleotidase targeting.
Similarly, the hydrolysis of ApnAs by NPP1 to NPP3 is
differentially inhibited by P2 receptor antagonists. Thus, the
application of P2 receptor inhibitors will potentially obscure
pharmacological experiments in which the effects of ApnAs on P2
receptors are investigated. ApnA hydrolysis and P2 receptors would
be simultaneously blocked. In addition, submilligram quantities of
heparin or heparan sulphate inhibit activity of NPPs in a variety
of cellular systems (71). Inhibition of alkaline phosphatase equally
varies between isoforms. TNAP is particularly sensitive to levamisole
and L-homoraginine. The other isoforms are sensitive to L-
phenylalanine (112). Ecto-5’-nucleotidase is inhibited by ATP and
ADP and by the non-hydrolyzable ADP analogue α,β-methylene
adenosine 5’-diphosphate (AOPCP) (51). Several NAD+ analogues
have been employed as inhibitors of CD38 (113) and P1P5-di
(adenosine-5') pentaphosphate (Ap5A) is a potent inhibitor of
adenylate kinase, inclusive its surface-located form (76).
ECTO-NUCLEOTIDASES IN THE NERVOUS SYSTEM
Since both nucleotides and nucleosides contribute to signaling
between neurons and also between glial cells and glia and neurons
(114, 115) it is expected that ecto-nucleotidases play an important
role in modulating and controlling these signaling pathways.
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Synaptic transmission: Some of the best evidence for a modulatory
role for ecto-nucleotidases in purinergic signal transmission stems
from investigations of the peripheral nervous system. Stable analogues
of ATP are up to a hundred times more potent than ATP in causing
smooth muscle contraction. ARL 67156 potentiates contractions
caused by nerve stimulation or application of ATP (116). This suggests
that ecto-nucleotidases tonically attenuate ATP-mediated signal
transmission, an effect relieved by the enzyme inhibitor. At
hippocampal synapses, ATP is rapidly hydrolyzed to adenosine that
in turn activates pre- or postsynaptic receptors, thereby modulating
synaptic transmission (79, 117, 118). In accordance with these
observations, the inhibitory synaptic effects of nucleotides or of
adenosine are abrogated in mice lacking A1 adenosine receptors (119).
Astrocyte signaling: ATP is a major extracellular mediator in the
propagation of Ca2+-waves between astrocytes in various brain
regions and within the retina. Ca2+-waves may be involved in the
modulation of synaptic transmission and in neuron-glia bi-
directional communication (120, 121). While inhibition of ecto-
nucleotidase activity facilitates and addition of potato apyrase
attenuates the physiological action of ATP in these experimental
settings, sites and extent of endogenous hydrolysis and the type of
endogenous ecto-nucleotidase involved need to be identified.
Microglia: Of all neuronal and glial cells, microglia stands out for
its high surface-located nucleotidase activity that has been identified
as NTPDase1 (61, 62). Ischemia enhances long-term microglial ecto-
nucleotidase expression. ATP stimulates microglia to release various
biologically active substances, induces chemotaxis of cultured
microglia and can, at high doses, induce microglial death (122). In
addition, spinal cord microglia is involved in inducing tactile allodynia
caused by peripheral nerve injury which is gated by P2X4 receptors
(123). The functional role of the very high microglial ecto-nucleotidase
activity needs to be elucidated. It may increase the threshold for ATP-
mediated microglial activation and the subsequent release of signaling
substances or may prevent receptor desensitization.
Cerebral vascular control: NTPDase1 knockout mice reveal
increased cerebral infarct volumes and reduced postischemic
perfusion following middle cerebral artery occlusion. Similarly, a
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recombinant soluble and catalytically active form of NTPDase1
restores postischemic cerebral perfusion and rescues from cerebral
injury (84, 124). The production of the antithrombotic metabolite
adenosine by endothelial ecto-5’-nucleotidase provides an additional
mechanism for down-regulating platelet aggregation. The functional
importance of vascular ecto-5’-nucleotidase in the formation of
extracellular adenosine from released adenine nucleotides has
recently been corroborated by the analysis of ecto-5’-nucleotidase
knockout mice (80, 125).
Adult neurogenesis: Ecto-nucleotidases are expressed on neural
progenitors and their expression pattern varies during development
of the nervous system (126). Recent work has established the
presence of stem cells in the adult mammalian brain. In the adult
murine brain, neurogenesis, the formation of new neurons from
neural progenitor cells, continuously takes place in two actively
proliferating zones, the subventricular zone (SVZ) of the lateral
ventricles and the dentate gyrus of the hippocampus. These cells
share properties of astrocytes and give rise to highly proliferating
intermediate cell types that finally mature and form neurons.
Interestingly, the ecto-ATPase NTPDase2 is highly and selectively
expressed by the stem cells (type B cells) of the SVZ (64) and by the
progenitor cells (residual radial glia) of the dentate gyrus (65). The
enzyme is no longer expressed by the progenitor cell-derived neurons.
Moreover, SVZ-derived stem cells cultured as neurospheres in the
presence of the growth factors EGF and FGF-2 express NTPDase2.
The enzyme becomes expressed in the neurogenic regions of the
rodent brain only during late gestation and thus is not involved in
embryonic neurogenesis. NTPDase2 represents a very useful and
reliable marker for the identification of adult neural stem cells.
Additional investigations revealed the expression of the tissue
non-specific form of alkaline phosphatase (TNAP) on all cell types of
the neurogenic SVZ, including stem cells, transient amplifying cells
and immature neuroblasts (D. Langer, unpublished). This imposes a
challenging scenario to the regulation of nucleotide signaling to the
densely interacting cellular elements of the neurogenic zone and
implies the functional involvement of both nucleotide and nucleoside
receptors. Indeed, neurosphere cells in vitro respond to P2 receptor
agonists and to adenosine with an increase in cell proliferation.
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Inhibition of the P2 receptors attenuates cell proliferation in spite of
the presence of mitogenic growth factors (127). Similarly, nucleotides
stimulate proliferation and dopaminergic differentiation of human
fetal midbrain neural precursor cells (128). These data provided
strong evidence that ecto-nucleotidases, nucleotides and nucleosides,
in concert with other signaling substances, can play a role in
controlling neurogenesis from resident stem cells in the adult
mammalian brain.
SYNOPSIS
Nucleotides control major physiological and pathophysiological
functions in every tissue and, due to the essentially ubiquitous
distribution of nucleotide and adenosine receptors, initiate a large
variety of cellular responses. They act as fast transmitters and,
presumably in the majority of cases, as modulators, often in
combination with other signaling molecules. Crosstalk between
nucleotide or nucleoside receptors with receptors for e.g. growth
factors has been demonstrated. This highlights the functional
significance of interactive pathways between nucleotides and other
cellular messengers. A major role of ecto-nucleotidases in these
settings is in the modulation of ligand availability for nucleotide and
nucleoside receptors. The understanding of the abundance of ecto-
nucleotidases and of their varying catalytic properties remains a
challenge but excellent examples for a cell or tissue-specific
association and function of individual enzymes have been elaborated.
Ecto-nucleotidases represent important therapeutic targets for
interfering with P2 or P1 receptor-mediated cellular signaling
pathways. The recent development of high throughput assays for
the development of ecto-nucleotidase inhibitors is expected to
considerably accelerate this long neglected aspect of nucleotide
research.
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